Posted by Michael Wonder on 28 Mar 2023
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit
28 March 2023 - The departure of the UK from the European Union and affiliated European regulatory bodies, including the European Medicines Agency, on 31 December 2020, has resulted in the Medicines and Healthcare products Regulatory Agency becoming an independent national regulator.
This change has required a fundamental transformation of the UK drug regulatory landscape, creating both opportunities and challenges for future development of oncology drugs.
